Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Inclusion Criteria

• •Resectable tumor measuring 2cm or more
• •Histologically documented, newly diagnosed, triple negative invasive breast cancer characterized by 0% immunohistochemistry (IHC) nuclear staining for ER-alpha, 0% IHC nuclear staining for PR-alpha, and no amplification of human epidermal growth factor receptor 2 (HER2)/neu by fluorescent in situ hybridization (FISH) using institutional standard; standard IHC assays for ER and PR use antibodies to ER-alpha and PR-alpha and PR-beta
• •Southwest Oncology Group (SWOG) performance status of less than or equal to 1
• •Absolute neutrophil count (ANC) \>= 1500/uL
• •Hemoglobin (Hgb) \>= 9 g/dL
• •Platelets \>= 100,000/uL
• •Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =\< 2.5 x upper limit of normal (ULN) or =\< 5.0 x ULN in patients with liver metastases
• •Creatinine =\< 2.0 mg/dL or calculated creatinine clearance \>= 50 ml/min
• •Albumin \>= 3 g/dL
• •Potassium \>= lower limit normal (LLN)
• •Phosphorous \>= LLN
• •Calcium \>= LLN
• •Magnesium \> LLN
• •Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment
• •Accessible for treatment and follow-up
• •Written informed consent prior to study entry